Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 5 min read

What is Sermorelin?

Sermorelin is a synthetic GHRH analogue studied for its effects on the GH-IGF-1 axis. This article summarises the research landscape, including animal and in vitro findings, and clarifies its status as a research compoun

peptides-pro Editorial

What is Sermorelin?

Sermorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It is also known as GHRH(1-29) or GRF(1-29) and belongs to the class of GHRH analogues. The peptide sequence corresponds to the first 29 amino acids of endogenous GHRH, and its molecular formula is C149H246N44O42S, with a molecular weight of approximately 3357.9 Da. These identifiers are consistent with its characterisation in analytical studies of GHRH analogues [12].

Sermorelin acts on the growth hormone-releasing hormone receptor (GHRHR) in the pituitary, stimulating the release of growth hormone (GH) and subsequently increasing insulin-like growth factor-1 (IGF-1) levels. This pathway is collectively referred to as the GH-IGF-1 axis [2].

Research Studies

Sermorelin and the GH-IGF-1 axis in performance-enhancing peptide research

Sermorelin is frequently included in reviews of performance-enhancing peptides that modulate the GH-IGF-1 axis. A 2025 review of the emerging landscape of such peptides listed sermorelin among GHRH analogues commonly encountered in clinical practice and online self-administration protocols, alongside tesamorelin and CJC-1295 [2]. The review noted that these agents are marketed as "research compounds" and are often unregulated. The same review discussed the broader class of growth hormone secretagogues, including GHRP-2, GHRP-6, hexarelin, and ipamorelin, as well as the GH fragment AOD9604 and IGF-1 analogues [2].

Sermorelin and analytical detection in urine

GHRH and its synthetic analogues, including sermorelin, are prohibited by the World Anti-Doping Agency (WADA). A 2025 study developed a nano liquid chromatography–quadrupole/orbitrap mass spectrometry method for the analysis of GHRH and its analogues in urine. The study reported that the analysis of these peptides presents significant analytical challenges due to their inherent in vivo instability and rapid clearance [12]. This work is reference-only and supports the characterisation of sermorelin as a performance-enhancing substance subject to anti-doping control.

Sermorelin and musculoskeletal injury research

A 2025 review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance described peptides as short chains of amino acids with a pharmacological niche between small-molecule drugs and large proteins. The review noted that their use in sports medicine is expanding, driven by patient demand for accelerated injury recovery and performance enhancement [9]. Sermorelin was not specifically evaluated in that review, but it falls within the broader category of peptides discussed. This evidence is reference-only and does not provide direct data on sermorelin.

Sermorelin and doping in sport

A 2025 critical review of peptide and peptide-analog drug use in recreational and professional sport and bodybuilding described the evolution from anabolic-androgenic steroids to peptides, including growth hormone secretagogues such as ipamorelin and GHRH analogues. The review reported that these agents are marketed as more selective and ostensibly safer alternatives [10]. Sermorelin is a GHRH analogue and is therefore relevant to this discussion, though the review did not focus on it exclusively. This evidence is reference-only.

Sermorelin and orthopaedic applications

A 2025 review of therapeutic peptides in orthopaedics discussed the ability of peptides to modulate molecular signalling networks central to cellular medicine, including the PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK pathways. The review reported that peptides exert influence over tissue regeneration and other processes [11]. Sermorelin was not specifically examined in this review, and the findings are not directly attributable to it. This evidence is reference-only.

Sermorelin and clinical research on GHRH analogues

While sermorelin itself has been studied in clinical settings, the available evidence in this block primarily concerns other GHRH analogues such as tesamorelin. For example, a Phase II trial is evaluating tesamorelin for reduction of liver fat in adults with fatty liver disease [3], and another trial is testing tesamorelin as an adjunct to exercise for improving physical function in people with HIV [4]. A separate study is investigating tesamorelin for nonalcoholic fatty liver disease and associated cardiovascular risk [6], and another is examining its effects on body composition in patients with HIV lipodystrophy and central adiposity [7]. A trial of GHRH in mild cognitive impairment is also underway [8]. These studies do not directly investigate sermorelin, but they provide context for the clinical research landscape of GHRH analogues.

Sermorelin and comparative studies

No head-to-head studies of sermorelin versus other GHRH analogues were identified in the provided evidence. A trial comparing a long Clomid protocol to a short protocol for ovarian stimulation includes a growth hormone-releasing hormone (GnRH) antagonist arm, but this is distinct from GHRH analogues and does not involve sermorelin [5].

Sermorelin and case reports

A case report described a 62-year-old male ex-military recreational bodybuilder with anterior cervical osteophyte-related dysphagia who had a history of long-term growth hormone use [1]. The report noted that the role of systemic anabolic factors in osteophyte growth is poorly characterised. Sermorelin was not mentioned in this case report, and the findings are not directly applicable to sermorelin research.

If you are reading this for personal health reasons

The material described here is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp